Hojjat Ahmadzadehfar1,2, Kambiz Rahbar3, Richard P Baum4, Robert Seifert3, Katharina Kessel3, Martin Bögemann5, Harshad R Kulkarni4, Jingjing Zhang4, Carolin Gerke6, Rolf Fimmers7, Clemens Kratochwil8, Hendrik Rathke8, Harun Ilhan9, Johanna Maffey-Steffan10, Mike Sathekge11, Levent Kabasakal12, Francisco Osvaldo Garcia-Perez13, Kalevi Kairemo14, Masha Maharaj15, Diana Paez16, Irene Virgolini10. 1. Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany. haf@klinukim-westfalen.de. 2. Department of Nuclear Medicine, Klinikum Westfalen, Am Knappschaftskrankenhaus 1, 44309, Dortmund, Germany. haf@klinukim-westfalen.de. 3. Department of Nuclear Medicine, University Hospital Muenster, Muenster, Germany. 4. Center for Radiomolecular Precision Oncology, Zentralklinik Bad Berka, Bad Berka, Germany. 5. Department of Urology, University Hospital Münster, Muenster, Germany. 6. Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany. 7. Institute for Medical Biometry, Informatics and Epidemiology, University of Bonn, Bonn, Germany. 8. Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany. 9. Department of Nuclear Medicine, LMU, University Hospital Munich, Munich, Germany. 10. Department of Nuclear Medicine, Medical University Innsbruck, Innsbruck, Austria. 11. Department of Nuclear Medicine, University of Pretoria & Steve Biko Academic Hospital, Pretoria, South Africa. 12. Department of Nuclear Medicine, Istanbul University, Istanbul, Turkey. 13. Department of Nuclear Medicine and Molecular Imaging, Instituto Nacional de Cancerología Mexico City, Mexico City, Mexico. 14. Docrates Cancer Center, Helsinki, Finland. 15. Department of Nuclear Medicine, Imaging and Therapy Centre, Durban, KwaZulu-Natal, South Africa. 16. Department of Nuclear Sciences and Applications, Nuclear Medicine and Diagnostic Imaging Section, IAEA, Vienna, Austria.
Abstract
INTRODUCTION: The impact of prior therapies, especially chemotherapy, on overall survival (OS) in patients with castration-resistant prostate cancer (CRPC) receiving [177Lu]Lu-PSMA-617 therapy has been the subject of controversy. Therefore, WARMTH decided to plan a multicenter retrospective analysis (the "617 trial") to evaluate response rate and OS as well as the impact of prior therapies on OS in more than 300 patients treated with 177Lu-PSMA-617. MATERIALS AND METHODS: The data of 631 metastatic CRPC (mCRPC) patients from 11 different clinics were evaluated. According to the inclusion and exclusion criteria, all patients had to have received at least abiraterone or enzalutamide prior to [177Lu]Lu-PSMA-617 therapy. The patients were divided into three groups: patients who had received prior chemotherapy, patients who avoided chemotherapy, and patients for whom a chemotherapy was contraindicated. RESULTS: The analysis included the data of 416 patients, with a median age of 71.9 years. At the time of analysis, 87 patients (20,9%) were still alive. A total of 53.6% of patients had received both abiraterone and enzalutamide; 75.5% and 26.4% had a history of chemotherapy with docetaxel and cabazitaxel, respectively. A total of 20.4% had had Ra-223. The median OS was 11.1 months. Prior chemotherapy, the existence of bone and liver metastases, as well as Eastern Cooperative Oncology Group (ECOG) status, were significant prognosticators of worse overall survival in both univariate and multivariate analyses. Patients without any prior chemotherapy showed a significantly longer OS (14.6 months). The median OS in patients who received one or two lines of chemotherapy with docetaxel or docetaxel followed by cabazitaxel, respectively, was 10.9 months and 8.9 months. There was no difference in OS between patients who had not received chemotherapy and patients for whom chemotherapy was contraindicated. The other prior therapies did not have any significant impact on OS. CONCLUSION: In the present multicenter analysis, chemotherapy-naïve mCRPC patients receiving [177Lu]Lu-PSMA-617 therapy had a significantly longer OS than patients with a history of chemotherapy. This remained independent in the multivariate analysis besides presence of bone and liver metastases as negative prognosticators for survival, whereas an ECOG of 0-1 is associated with a longer OS.
INTRODUCTION: The impact of prior therapies, especially chemotherapy, on overall survival (OS) in patients with castration-resistant prostate cancer (CRPC) receiving [177Lu]Lu-PSMA-617 therapy has been the subject of controversy. Therefore, WARMTH decided to plan a multicenter retrospective analysis (the "617 trial") to evaluate response rate and OS as well as the impact of prior therapies on OS in more than 300 patients treated with 177Lu-PSMA-617. MATERIALS AND METHODS: The data of 631 metastatic CRPC (mCRPC) patients from 11 different clinics were evaluated. According to the inclusion and exclusion criteria, all patients had to have received at least abiraterone or enzalutamide prior to [177Lu]Lu-PSMA-617 therapy. The patients were divided into three groups: patients who had received prior chemotherapy, patients who avoided chemotherapy, and patients for whom a chemotherapy was contraindicated. RESULTS: The analysis included the data of 416 patients, with a median age of 71.9 years. At the time of analysis, 87 patients (20,9%) were still alive. A total of 53.6% of patients had received both abiraterone and enzalutamide; 75.5% and 26.4% had a history of chemotherapy with docetaxel and cabazitaxel, respectively. A total of 20.4% had had Ra-223. The median OS was 11.1 months. Prior chemotherapy, the existence of bone and liver metastases, as well as Eastern Cooperative Oncology Group (ECOG) status, were significant prognosticators of worse overall survival in both univariate and multivariate analyses. Patients without any prior chemotherapy showed a significantly longer OS (14.6 months). The median OS in patients who received one or two lines of chemotherapy with docetaxel or docetaxel followed by cabazitaxel, respectively, was 10.9 months and 8.9 months. There was no difference in OS between patients who had not received chemotherapy and patients for whom chemotherapy was contraindicated. The other prior therapies did not have any significant impact on OS. CONCLUSION: In the present multicenter analysis, chemotherapy-naïve mCRPC patients receiving [177Lu]Lu-PSMA-617 therapy had a significantly longer OS than patients with a history of chemotherapy. This remained independent in the multivariate analysis besides presence of bone and liver metastases as negative prognosticators for survival, whereas an ECOG of 0-1 is associated with a longer OS.
Authors: Clemens Kratochwil; Wolfgang Peter Fendler; Matthias Eiber; Richard Baum; Murat Fani Bozkurt; Johannes Czernin; Roberto C Delgado Bolton; Samer Ezziddin; Flavio Forrer; Rodney J Hicks; Thomas A Hope; Levant Kabasakal; Mark Konijnenberg; Klaus Kopka; Michael Lassmann; Felix M Mottaghy; Wim Oyen; Kambiz Rahbar; Heiko Schöder; Irene Virgolini; Hans-Jürgen Wester; Lisa Bodei; Stefano Fanti; Uwe Haberkorn; Ken Herrmann Journal: Eur J Nucl Med Mol Imaging Date: 2019-08-22 Impact factor: 9.236
Authors: Axel Bräuer; Lena Sophie Grubert; Wolfgang Roll; Andres Jan Schrader; Michael Schäfers; Martin Bögemann; Kambiz Rahbar Journal: Eur J Nucl Med Mol Imaging Date: 2017-06-17 Impact factor: 9.236
Authors: Kambiz Rahbar; Martin Bögeman; Anna Yordanova; Maria Eveslage; Michael Schäfers; Markus Essler; Hojjat Ahmadzadehfar Journal: Eur J Nucl Med Mol Imaging Date: 2017-11-13 Impact factor: 9.236
Authors: Hojjat Ahmadzadehfar; Simone Wegen; Anna Yordanova; Rolf Fimmers; Stefan Kürpig; Elisabeth Eppard; Xiao Wei; Carl Schlenkhoff; Stefan Hauser; Markus Essler Journal: Eur J Nucl Med Mol Imaging Date: 2017-05-09 Impact factor: 9.236
Authors: Michael S Hofman; Louise Emmett; John Violet; Alison Y Zhang; Nicola J Lawrence; Martin Stockler; Roslyn J Francis; Amir Iravani; Scott Williams; Arun Azad; Andrew Martin; Margaret McJannett; Ian D Davis Journal: BJU Int Date: 2019-10-22 Impact factor: 5.588
Authors: Yuri Tolkach; Heidrun Gevensleben; Ralph Bundschuh; Aydan Koyun; Daniela Huber; Christina Kehrer; Thomas Hecking; Mignon-Denise Keyver-Paik; Christina Kaiser; Hojjat Ahmadzadehfar; Markus Essler; Walther Kuhn; Glen Kristiansen Journal: Breast Cancer Res Treat Date: 2018-02-17 Impact factor: 4.872
Authors: Lucia Zisser; Josef Yu; André Oszwald; Tim Wollenweber; Elisabeth Kretschmer-Chott; Bernhard Grubmüller; Gero Kramer; Shahrokh F Shariat; Markus Mitterhauser; Chrysoula Vraka; Marcus Hacker; Alexander R Haug; Sazan Rasul Journal: Nucl Med Commun Date: 2022-09-19 Impact factor: 1.698
Authors: Finn Edler von Eyben; Glenn Bauman; Rie von Eyben; Kambiz Rahbar; Cigdem Soydal; Alexander R Haug; Irene Virgolini; Harshad Kulkarni; Richard Baum; Giovanni Paganelli Journal: Int J Mol Sci Date: 2020-11-28 Impact factor: 5.923
Authors: Sazan Rasul; Tim Wollenweber; Lucia Zisser; Elisabeth Kretschmer-Chott; Bernhard Grubmüller; Gero Kramer; Shahrokh F Shariat; Harald Eidherr; Markus Mitterhauser; Chrysoula Vraka; Werner Langsteger; Marcus Hacker; Alexander R Haug Journal: Cancers (Basel) Date: 2021-05-20 Impact factor: 6.639
Authors: Mike M Sathekge; Frank Bruchertseifer; Mariza Vorster; Alfred Morgenstern; Ismaheel O Lawal Journal: Eur J Nucl Med Mol Imaging Date: 2021-06-26 Impact factor: 9.236